Biocodex has acquired two licenses from THX Pharma to develop and commercialize Batten-1 worldwide and TX01 in the United States and Canada. The total deal value is up to €173 million, including a €12 ...
THX Pharma (Theranexus) and Biocodex have entered a strategic licensing agreement to further the development of two drug candidates, Batten-1 and TX01, targeted at the Batten, Gaucher, and ...
THX Pharma (Theranexus) and Biocodex, an independent international pharmaceutical group, today announced the execution of a strategic licensing agreement to advance the development of two drug ...
Biocodex obtained an exclusive worldwide license for Batten-1 and an exclusive US/Canada license for TX01, while THX Pharma retains leadership of clinical development for both assets. Total ...
55 years later, the sci-fi cult classic THX 1138 remains a must for Star Wars fans ...
Lyon, France – March 25, 2026, 6:30 pm CET – THX Pharma (Theranexus), an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces the publication of its ...
THX Pharma, a biopharmaceutical company specializing in the development of innovative treatments for rare diseases and Biocodex, an independent international pharmaceutical group, announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results